Oxcarbazepine Suspension
Product Images NDC 72205-354

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 72205-354). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxocarbazepine-bottle-lbl (Oxocarbazepine Bottle Lbl)

Label for Oxcarbazepine Oral Suspension USP, 300 mg/5 mL, 250 mL bottle. The label includes storage instructions, dosage advisory to shake well before using, and pharmacist dispensing guidance. Manufactured by MSN Pharmaceuticals Inc. and distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ. It features barcode and contact information for the distributor.*

FDA Label Image

Oxocarbazepine-carton-lbl (Oxocarbazepine Carton Lbl)

Packaging label for Oxcarbazepine Oral Suspension, USP 300 mg/5 mL, 250 mL bottle. The label displays the product name, concentration, and volume, with instructions to shake well before use and a note for pharmacists to dispense with a medication guide. Manufactured by MSN Pharmaceuticals Inc. and distributed by Novadoz Pharmaceuticals LLC. The label includes storage instructions and a barcode.*

FDA Label Image

Oxocarbazepine-os-fig-01 (Oxocarbazepine Os Fig 01)

FDA Label Image

Oxocarbazepine-os-fig-02 (Oxocarbazepine Os Fig 02)

Oxcarbazepine 300 mg/5 mL oral suspension in a brown glass bottle with a child-resistant white cap, labeled by Novadoz Pharmaceuticals LLC. The bottle is clear with no visible external packaging or label text shown in the image.*

FDA Label Image

Oxocarbazepine-os-fig-03 (Oxocarbazepine Os Fig 03)

An instructional line drawing illustration of a medical syringe indicating the parts labeled 'Barrel' and 'Plunger.' This diagram visually identifies key components of a standard syringe, without any pharmaceutical product branding or labeling.*

FDA Label Image

Oxocarbazepine-os-fig-04 (Oxocarbazepine Os Fig 04)

Instructional illustration depicting a hand holding and shaking a small bottle, indicating the suspension should be shaken before use.*

FDA Label Image

Oxocarbazepine-os-fig-05 (Oxocarbazepine Os Fig 05)

An instructional illustration showing a bottle with an arrow pointing down on the cap and a curved arrow indicating the cap should be twisted or turned to open.*

FDA Label Image

Oxocarbazepine-os-fig-06 (Oxocarbazepine Os Fig 06)

An instructional illustration showing hands twisting off the cap of a dark-colored oral suspension bottle with a separate cap placed nearby. This image likely demonstrates opening the 300 mg/5mL oxcarbazepine suspension bottle from Novadoz Pharmaceuticals LLC.*

FDA Label Image

Oxocarbazepine-os-fig-07 (Oxocarbazepine Os Fig 07)

An instructional illustration showing a hand holding and shaking a bottle, indicating that the suspension medication should be shaken before use. The bottle has a cap and is depicted with motion lines to represent shaking.*

FDA Label Image

Oxocarbazepine-os-fig-08 (Oxocarbazepine Os Fig 08)

An instructional illustration showing a hand holding an oral suspension bottle with a dosing syringe being inserted into the bottle's opening. An arrow indicates the downward direction of the syringe insertion. This diagram likely demonstrates how to properly withdraw the OXCARBAZEPINE oral suspension dose from the bottle.*

FDA Label Image

Oxocarbazepine-os-fig-09 (Oxocarbazepine Os Fig 09)

An instructional illustration showing a hand holding a bottle of oral suspension with a measuring syringe attached to the bottle's opening. The diagram indicates the use of the syringe for measuring the correct dose from the suspension bottle.*

FDA Label Image

Oxocarbazepine-os-fig-10 (Oxocarbazepine Os Fig 10)

Illustration showing how to measure oral suspension in a dosing syringe for Oxcarbazepine 300 mg/5 mL. It contrasts incorrect measurements with large air bubbles and a correct measurement with small air bubbles, demonstrating proper technique for accurate dosing.*

FDA Label Image

Oxocarbazepine-os-fig-11 (Oxocarbazepine Os Fig 11)

An instructional illustration showing how to measure a dose of oral suspension using a syringe. The image depicts a hand holding an oral suspension bottle inverted above a syringe, with an inset close-up of the syringe's graduated measurement markings to guide correct dosing.*

FDA Label Image

Oxocarbazepine-os-fig-12 (Oxocarbazepine Os Fig 12)

An instructional illustration showing a hand holding a syringe and drawing liquid from an open bottle. An arrow indicates the syringe is being rotated or withdrawn, suggesting how to properly use the syringe to measure the suspension accurately.*

FDA Label Image

Oxocarbazepine-os-fig-13 (Oxocarbazepine Os Fig 13)

An instructional illustration showing a child being administered an oral suspension medication with a syringe. The image also depicts a hand dispensing liquid from a syringe into a small cup, demonstrating proper dosage measurement or administration technique for an oral suspension drug.*

FDA Label Image

Oxocarbazepine-os-graph-01 (Oxocarbazepine Os Graph 01)

A Kaplan-Meier survival curve chart comparing the exit rates over time in days between two treatment groups: Oxcarbazepine and Placebo. The chart includes a log-rank test p-value of 0.0001, indicating a statistically significant difference between groups.*

FDA Label Image

Oxocarbazepine-os-graph-02 (Oxocarbazepine Os Graph 02)

A Kaplan-Meier survival curve showing the seizure rate over time in days from the first dose to the first seizure. The graph compares two treatment groups: Oxcarbazepine and Placebo. The curve for the Placebo group shows a higher seizure rate over time compared to the Oxcarbazepine group. A log-rank test p-value of 0.046 is indicated, suggesting a statistically significant difference between the groups.*

FDA Label Image

Oxocarbazepine-os-graph-03 (Oxocarbazepine Os Graph 03)

A Kaplan-Meier survival curve chart showing exit rates over time in days, comparing high and low dose groups and treatment groups of Oxcarbazepine versus placebo. The y-axis represents the exit rate from 0 to 1, and the x-axis shows time to exit in days up to 130. The chart includes statistical notation of a log-rank test p-value of 0.0001.*

FDA Label Image

Oxocarbazepine-os-graph-04 (Oxocarbazepine Os Graph 04)

A Kaplan-Meier survival curve plot showing exit rate versus time to exit in days for two treatment groups labeled 'HIGH' and 'LOW'. The graph includes a p-value of 0.0001 from a log-rank test, indicating a comparison between the two groups over time.*

FDA Label Image

Oxocarbazepine-os-structure (Oxocarbazepine Os Structure)

Chemical structure diagram of oxcarbazepine, a human prescription drug active ingredient. The structure shows oxcarbazepine's molecular framework including ring systems and functional groups. The image is consistent with the label for oxcarbazepine oral suspension 300 mg/5 mL by Novadoz Pharmaceuticals LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.